ArticleACS omega2026
ROS-Scavenging Bamboo-Derived Carbon Dot-Methotrexate Nanocomposite Ameliorates Rheumatoid Arthritis through Dual Therapeutic Mechanisms.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bamboo-Enabled Nanomaterials for Biomedical Applications.Polymers · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a common chronic immune-mediated inflammatory disease. Current treatment strategies for RA are limited and often associated with significant adverse effects. Methotrexate (MTX), a first-line therapeutic agent for RA, demonstrates efficacy; however, its adverse effects remain a concern, particularly its tendency to increase reactive oxygen species (ROS) levels and exacerbate oxidative stress. In this study, we developed an MTX/CD complex by combining MTX with bamboo leaf-derived carbon dots (CDs). Experimental results showed that the MTX/CD complex effectively reduced ROS generation and significantly mitigated oxidative stress, while retaining the favorable therapeutic effect of MTX against RA. Moreover, the composite more effectively suppressed the abnormal proliferation of rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS), thereby alleviating joint symptoms in RA patients and offering a novel therapeutic strategy for RA management.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.